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pharmacoeconomic evaluation of
antibiotics for the treatment of patients
infected with complicated skin and soft
structure infection and hospital-acquired or
ventilator-associated penumonia
Ying Zhang1†, Yan Wang1,2†, Mieke L. Van Driel3, Treasure M. McGuire2,4,5, Tao Zhang1, Yuzhu Dong1, Yang Liu1,
Leichao Liu1, Ruifang Hao1, Lu Cao6, Jianfeng Xing6* and Yalin Dong1*Abstract
Background: Infections due to methicillin-resistant Staphylococcus aureus (MRSA) cause serious health risks and
significant economic burdens and the preferred drugs are still controversial.
Methods: We performed a network meta-analysis (NMA) to compare the efficacy and safety of antibiotics used to
treat inpatients with complicated skin and soft structure infections (cSSSI) or hospital-acquired or ventilator-
associated pneumonia (HAP/VAP). We also developed a decision tree model to assess the cost-effectiveness of
antibiotics.
Results: Forty-nine randomized controlled trials met the inclusion criteria (34 for cSSSI, 15 for HAP/VAP) and
compared the efficacy and safety of 16 antibiotics. For cSSSI, NMA indicated that for clinical cure, linezolid was
superior than vancomycin (odds ratio (OR) 1.55, 95% confidence interval (CI) 1.19–2.02), while tedizolid (OR 1.39, CI
0.70–2.76) was similar to vancomycin. In terms of safety, there were no significant differences between any two
interventions on total adverse events. Based on drug and hospital costs in America, the incremental cost-
effectiveness ratios (ICERs) per life-year saved for linezolid and tedizolid compared with vancomycin were US$2833
and US$5523. For HAP/VAP, there were no significant effects either for clinical cure or for safety endpoints between
linezolid and vancomycin in NMA. ICERs per life-year saved for linezolid compared with vancomycin were US$2185.
Conclusion: In these clinical trials, considering efficacy, safety, and cost-effectivenes, linezolid and tedizolid showed
their superiority in MRSA cSSSI; while linezolid might be recommended to treat MRSA pneumonia. Although
vancomycin was not cost-effective in pharmacoeconomic evaluation, it is still the first-line treatment for MRSA
infection in the clinical practice. This study might provide new insights of therapeutic choices for patients with
MRSA infections whilst awaiting the arrival of higher quality evidence.© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Methicillin-resistant Staphylococcus aureus (MRSA) in-
fections have posed a global threat since the end of the
last century. MRSA infections cause increased mortality,
cost burden and longer hospital stay [1]. Resistance
tracking by SENTRY highlights the increasing preva-
lence of MRSA for two infections in which S. aureus
predominates: complicated skin and soft-structure infec-
tions (cSSSIs); and hospital-acquired pneumonia (HAP)
or ventilator-associated pneumonia (VAP) [2, 3].
The Infectious Diseases Society of America (IDSA) [4]
published clinical practice guidelines for the treatment
of MRSA infections, providing a practical basis for man-
agement. The glycopeptide vancomycin has been recom-
mended by IDSA guidelines of MRSA treatment for
many decades due to its excellent antibacterial activity
[5]. However, in the latest decade, minimum inhibitory
concentration (MIC) ‘creep’ among susceptible strains to
vancomycin has been observed among MRSA isolates in
USA, this has been consistently associated with in-
creased mortality [6, 7].
In addition, there has recently been a sharp rise in the
incidence of infections caused by MRSA [8, 9]. This has
resulted in increased use of vancomycin and the emer-
gence of vancomycin resistant S. aureus [9, 10]. As a
consequence, there has been an emergence of new anti-
biotics to combat the evolving resistance of this challen-
ging pathogen [11]. Linezolid, daptomycin, tigecycline,
new glycopeptides such as telavancin and ceftaroline
have been approved to treat MRSA infections. While
meta-analyses [12–15] which have compared the efficacy
and safety of vancomycin with linezolid or other antibiotics
has been published; the results of these studies are not con-
sistent and definitive conclusions cannot be drawn.
In this paper, we compared different antibiotics used
for the treatment of MRSA infections using the tech-
nique of network meta-analysis (NMA) to determine
which antibiotic(s) achieve the superior therapeutic ef-
fect. This approach can simultaneously assess multiple
interventions in combination with direct and indirect
evidence, thereby synthesizing available evidence. In
addition, we developed a pharmacoeconomic analysis
model from the patient perspective to investigate the
cost-effectiveness of these antibiotics using clinical effi-
cacy data generated by the NMA and medical data.
Materials and methods
Search strategy and selection criteria
A network meta-analysis of randomized controlled trials
(RCTs) was performed in compliance with the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines [16]. We searched PubMed, EMBASE,
and the Cochrane Central Register of Controlled Trials for
RCTs published up to September 2018, using the searchstrategies described in Additional file 1: Appendix A. We
also searched ClinicalTrials.gov for any relevant completed
studies and hand searched the references from the retrieved
RCTs.
Study selection and data extraction
Infections qualifying for this research were cSSSIs [17]
and HAP/VAP in adult patients [18, 19]. However, most
of the studies we included were published prior to the
Food and Drug Administration (FDA) guidance on de-
signing RCTs to evaluate drugs for cSSSIs [20], with the
results that the definition of cSSSI varied between stud-
ies. Therefore, we did not present a clear definition to
avoid misunderstanding. HAP is defined as pneumonia
that occurs 48 h or more after admission, which was not
incubating at admission [21, 22]. VAP refers to pneumo-
nia that occurs within 48–72 h after endotracheal intub-
ation [21, 23]. To minimise clinical heterogeneity and
because it is difficult to predict to what extent the in-
creased prevalence of community-associated MRSA
(CA-MRSA) will be accompanied by enhanced toxicity
[24–27], we did not evaluate CA-MRSA infections.
The following eligibility criteria were applied: RCTs includ-
ing adult patients with MRSA-related infections, and involv-
ing antibiotics with anti-MRSA activity. Studies were
excluded if: (1) non-English language, (2) involving
colonization or infection prevention, (3) pharmacokinetic/
pharmacodynamic studies, (4) the research only evaluated
pharmacoeconomics or pooled analysis. Two researchers
(YZ and YW) independently assessed the citations against
the above eligibility criteria. Disagreements about study selec-
tion and data extraction were resolved through consensus.
The following data were extracted: authors, year of
publication, patient population, study design, baseline
characteristics, interventions (antibiotics for MRSA in-
fections), clinical outcomes and sponsorship.
Outcomes and quality assessment
The primary outcome was clinical success at test of cure
(TOC) in the modified intention-to-treat (mITT) popu-
lation, which was determined cured and improved.
Cured was defined as resolution of the clinical signs and
symptoms of infection when compared with baseline;
improved was defined as improvement in two or more,
but not all, clinical signs and symptoms of infection
when compared with baseline. The intent-to-treat (ITT)
population included all patients randomized into the
study. The mITT population was randomized patients
receiving at least one dose of the study drug. The second-
ary endpoints included clinical efficacy in the clinically
evaluable (CE) population and microbiological eradication
in the microbiologically evaluable (ME) population. We
also evaluated overall and serious adverse events and
all-cause mortality in the safety population as safety
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in each trial, we did not give specific time frame of mortal-
ity. The safety population was the primary population for
all the safety analyses, and consisted of all patients who
were dosed with study drug, irrespective of randomization.
Since the included RCTs used different definitions for ad-
verse events, such as nephrotoxicity and thrombocytopenia,
the safety was assessed according to each RCT’s own
definition.
We evaluated the quality of included RCTs using the
Cochrane risk of bias assessment tool in Review Man-
ager version 5.3.
Pharmacoeconomic analysis model
We conducted a decision-analytic model from the pa-
tient perspective to assess the outcomes of antibiotic
therapy with antibiotics in patients with MRSA infec-
tions using TreeAge Pro 2011 (TreeAge Software, Inc.,
MA, USA). The decision tree model followed first-line
and second-line therapy for MRSA cSSSI or HAP/VAP
(see Additional file 1: Figure B.1).
Vancomycin was considered as comparator in the
MRSA cSSSI model and the pneumonia model. The cure
rate of the first-line treatment for the comparator was ex-
tracted from the pooled data of pairwise meta-analysis.
The ORs of clinical cure for the comparator versus each
antibiotic were obtained from NMA to generate the prob-
abilities for comparator agents. The key outcomes of life-
time costs and life-years (LYs) saved for the two types of
MRSA infections. The incremental cost-effectiveness ra-
tios (ICERs) per LY saved was calculated, which was used
to compare the performance of treatment strategies. We
did not adjust for quality of life because we assumed that
survivors of MRSA infections are unlikely to have
long-term consequences related to this condition (i.e., util-
ity value = 1) [28]. We considered each treatment strategy
resulting in an effect size less than the willingness-to-pay
(WTP) threshold ($50,000) to be acceptable [29].
One-way sensitivity analyses were conducted to test how
variation in one variable could affect model results. Prob-
abilistic sensitivity analysis was carried out with 1000
times of Monte Carlo simulations to evaluate the impact
of all variables simultaneously. The model and associated
deterministic sensitivity analysis were developed from the
patient perspective, with all costs are presented in 2017
US dollars with a conversion rate of 3% [30] (add-
itional details of the cost-effectiveness methodology in
Additional file 1: Appendix B).
Statistical analysis
We conducted two types of meta-analyses. First, we per-
formed pairwise meta-analysis with a random-effects
model. The estimates of primary and secondary out-
comes were determined using odds ratios (OR) and theircorresponding 95% confidence intervals (CI). Secondly,
we conducted a random-effects network meta-analysis
for direct and indirect comparisons [31]. In order to es-
timate the rank order for all interventions, surface under
the cumulative ranking curve (SUCRA) probabilities
were reported for primary outcome and safety outcome
[32]. To check for the presence of inconsistency, we
used the transitivity assumption to assess consistency of
our assumption by comparing direct and indirect overall
effects [33]. A common estimate (the tau [τ] value) was
assumed to evaluate the heterogeneity for all compari-
sons. To examine the robustness of the estimates with
different baseline characteristics, sensitivity network
meta-analyses for primary outcomes were performed on
the following variables: sex ratio, age and restricting to
low-risk of bias studies. We used Stata (Version 13.0)
for the analyses (additional details of the statistical ana-
lysis of meta-analysis in Additional file 1: Appendix C).
Results
Characteristics of included trials
Of 3879 potentially relevant articles identified through
the literature search, 3794 were excluded after the initial
screening (Fig. 1). We reviewed the full text of the
remaining 85 studies. We excluded 36 studies for the
following reasons: pooled studies (n = 16), non-adult pa-
tients (n = 10), reviews or meta-analyses (n = 10). Finally,
49 trials studying 16 different antibiotics met the criteria
(34 for cSSSI, 15 for pneumonia) and were included in
the NMA. The main characteristics of the included stud-
ies are shown in Additional file 1: Appendix D. The eli-
gible comparison networks with MRSA cSSSI and
pneumonia respectively are shown in Figs. 2 and 3.
The risk of bias summary and graph are listed in
Additional file 1: Appendix E. Some studies were assessed as
unclear risk of bias as they did not provide details about
randomization, allocation concealment and blinding. The
majority of studies are randomized, double-blind, controlled
trials. Six studies reported evidence of blinding of partici-
pants and personnel. Most of the studies were sponsored by
pharmaceutical companies (42 RCTs, 87%).
Pairwise and network meta-analysis of cSSSI
For cSSSI, all 34 included studies reported clinical cure
rate in the mITT population. Pairwise meta-analysis
showed that linezolid was more effective than vanco-
mycin (OR 1.23, 95% CI 1.09–1.50, I2 = 0.0%) (Table 1),
which was consistent with the results of the NMA (OR
1.55, 95% CI 1.19–2.02) (Fig. 4). Moreover, among pa-
tients with MRSA cSSSI, omadacycline was found to
have a superior clinical response compared to all antibi-
otics except trimethoprim/sulfamethoxazole plus rifam-
picin (SXT/rifampin) (Fig. 4). Only 14 studies assessed
the microbiological eradication of the ME population.
Fig. 1 Study selection flow diagram. RCT, randomized controlled trial. cSSSI, complicated skin and soft structure infection
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cantly superior to vancomycin (OR 1.93, 95% CI 1.26–
2.96) in the microbiological response, which was consist-
ent with the results of NMA (OR 2.42, 95% CI 1.21–
4.86) (see Additional file 1: Table F.1 and Figure F.1).
The majority of studies reported data on adverse events.
There were no significant differences between any two in-
terventions in terms of all-cause mortality rates in MRSA
cSSSI patients. Telavancin had a higher total number of
adverse events compared to vancomycin both in pairwise
(OR 1.35, 95% CI 1.14–1.60) and network meta-analyses
(OR 1.25, 95% CI 1.10–1.73) (see Additional file 1: Table
F.2). The incidence of nephrotoxicity was similar between
linezolid and vancomycin in head-to-head comparisons.
Risk for thrombocytopenia was not statistically signifi-
cantly different among linezolid and others in pairwise
meta-analysis. Gastrointestinal adverse events were com-
mon with all included antibiotics in the treatment of
MRSA cSSSI. (see Additional file 1: Table F.2).
The efficacy and safety of 15 interventions for the
treatment of MRSA cSSSI are presented via the surfaceunder the cumulative ranking curve (SUCRA) values
which display the probability of each increasing rank order
for efficacy and safety (see Additional file 1: Tables F.3 and
F.4). In terms of efficacy, NMA found antibiotics ranked
first to fourth via SUCRA values were omadacycline, SXT/
rifampin, JNJ-Q2, and oxazolidinone. In terms of safety,
the lowest ranked antibiotic was telavancin.
Pairwise and network meta-analysis of HAP/VAP
In the smaller HAP network of studies, pairwise meta-
analysis showed that for clinical cure rate linezolid was
similar to vancomycin in the mITT population (OR 1.11,
95% CI 0.91–1.34, I2 = 0.0%) (Table 1), which was con-
sistent with the NMA results (OR 1.20, 95% CI 0.96–
1.50) (Fig. 5). In addition, the NMA of pneumonia trials
found that for clinical cure rate there was no difference
between teicoplanin and linezolid or teicoplanin and
vancomycin (Fig. 5). The results of the head-to-head
comparisons and NMA of different antibiotics in the
ME population are listed in Additional file 1: Table G.1
and Figure G.1. Safety results of antibiotics are reported
Fig. 2 Network plot of eligible comparisons for primary outcome in cSSSI group. The size of the node corresponds to the number of individual
studies. The directly compared interventions are linked with a line, the width of which is proportional to the number of studies assessing
respective comparisons. Numbers above the lines indicate studies. SXT, trimethoprim/sulfamethoxazole. JNJ-Q2, a novel fluoroquinolone
Fig. 3 Network plot of eligible comparisons for primary outcome in HAP/VAP group. The size of the node corresponds to the number of
individual studies. The directly compared interventions are linked with a line, the width of which is proportional to the number of studies
assessing respective comparisons. Numbers above the lines indicate studies. SXT, trimethoprim/sulfamethoxazole
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Table 1 Pairwise meta-analysis of antibiotics of clinical cure in cSSSI and HAP/VAP in mITT population
Treatment comparisons Number of studies Pairwise meta-analysis
Odds ratio (95% CI)
P value Heterogeneity I2, % (variation in OR
attributable to heterogeneity)
cSSSI
Vancomycin vs Oritavancin 2 0.96 (0.59, 1.56) 0.867 0.0
Vancomycin vs Daptomycin 4 1.04 (0.79, 1.36) 0.756 0.0
Vancomycin vs Telavancin 4 0.86 (0.61, 1.24) 0.430 0.0
Vancomycin vs Tigecycline 3 1.15 (0.79, 1.66) 0.451 0.0
Vancomycin vs Ceftaroline 4 0.94 (0.71, 1.26) 0.695 0.0
Vancomycin vs Dalbavancin 2 1.00 (0.77, 1.31) 0.973 0.0
Vancomycin vs Ceftobiprole 2 0.78 (0.33, 1.82) 0.565 0.0
Linezolid vs Vancomycin 5 1.23 (1.09, 1.50) 0.006 0.0
Linezolid vs Dalbavancin 1 0.84 (0.39, 1.82) 0.673 –
Linezolid vs SXT/rifampicin 1 0.70 (0.16, 2.95) 0.627 –
Linezolid vs Omadacycline 1 0.36 (0.03, 4.18) 0.417 –
Linezolid vs Fusidic Acid 1 2.71 (0.83, 8.89) 0.099 –
Linezolid vs JNJ-Q2 1 0.95 (0.45, 1.94) 0.682 –
Linezolid vs Tedizolid 2 1.09 (0.58, 2.02) 0.780 0.0
Linezolid vs Teicoplanin 1 0.52 (0.15, 1.79) 0.234 –
HAP/VAP
Vancomycin vs Telavancin 2 1.02 (0.85, 1.23) 0.822 0.0
Vancomycin vs Vancomycin/rifampicin 1 1.49 (0.72, 3.06) 0.278 –
Vancomycin vs Quinupristin/dalfopristin 1 1.03 (0.71, 1.51) 0.858 –
Linezolid vs Vancomycin 8 1.11 (0.91, 1.34) 0.301 0.0
Linezolid vs Ceftobiprole 1 0.53 (0.17, 1.57) 0.251 –
Linezolid vs Teicoplanin 1 0.38 (0.07, 2.16) 0.279 –
Linezolid vs SXT/rifampicin 1 1.77 (0.25, 12.45) 0.562 –
cSSSI complicated skin and soft structure infection, HAP/VAP hospital-acquired or ventilator-associated pneumonia, mITT modified intention-to-treat population,
JNJ-Q2 a novel fluoroquinolone, SXT trimethoprim/sulfamethoxazole
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ported on adverse events, and there was no significant
difference between any two treatments for total adverse
events. The incidence of nephrotoxicity of vancomycin
was similar to linezolid (OR 1.02, 95% CI 0.93–1.12).
The difference was also not statistically significant be-
tween vancomycin and linezolid for the incidence of
thrombocytopenia (OR 0.99, 95% CI 0.86–1.55). Gastro-
intestinal adverse events were common with all antibi-
otics in the treatment of MRSA pneumonia (see
Additional file 1: Table G.2).
NMA of MRSA pneumonia trials showed that ceftobi-
prole ranked first about efficacy, followed by teicoplanin,
linezolid, and vancomycin (see Additional file 1: Table
G.3). While vancomycin ranked first according to safety
(see Additional file 1: Table G.4).
Assessment of heterogeneity and inconsistency
No significant heterogeneity within pairwise compar-
isons of antibiotics was found (Table 1). The valuesof heterogeneity variables for clinical cure rate in the
mITT population, microbiological response in the
ME population, clinical cure rate in the CE popula-
tion and the incidence of total adverse events were
τ = 0.09, τ = 0.33 τ = 0.43, τ = 0.18, respectively (all
values indicated moderate heterogeneity). In the in-
consistency test only one closed loop (Dalbavancin--
Linezolid-Vancomycin) was detected and the results
are shown in Additional file 1: Appendix H. There
were no substantial differences between direct and
indirect treatment effect estimates and therefore no
evidence of inconsistency in the cSSSI network. In
the MRSA pneumonia network, indirect evidence
was hardly obtained in the presence of direct evi-
dence for any interventions, hence an inconsistency
test was not performed.
Sensitivity analysis
The results of the post hoc sensitivity analysis of
MRSA cSSSI and pneumonia are presented in
Fig. 4 Network meta-analysis of clinical cure in cSSSI in mITT population. Comparisons should be read from left to right. The safety estimate is
located at the intersection of the column-defining treatment and the row-defining treatment. Significant results are in bold and underlined. cSSSI,
complicated skin and soft structure infection. mITT, modified intention-to-treat population. JNJ-Q2, a novel fluoroquinolone. VAN, vancomycin.
LIN, linezolid. CEF1, ceftaroline. CEF2, ceftobiprole. SXT/RIT, trimethoprim/sulfamethoxazole plus rifampicin. ORI, oritavancin. DAL, dalbavancin. DAP,
daptomycin. TEL, telavancin. TIG, tigecyline. TEI, teicoplanin. OMA, omadacycline. FA, fusidic acid. JNJ-Q2, a novel fluoroquinolone. TED, tedizolid.
OR, odds ratio. CI, confidence interval
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lid and tedizolid showed more effective than other
antibiotics when high risk studies were excluded (i.e.,
SXT/rifampin in cSSSI). Linezolid and vancomycin
were superior to other antibiotics in pneumonia after
including the research with high-risk of bias (high
risk studies were excluded, i.e., teicoplanin in pneu-
monia). The efficacy rankings were robust after
adjusting for the mean age and sex ratios. The
comparison-adjusted funnel plots showed no asym-
metry in Additional file 1: Appendix I.Fig. 5 Network meta-analysis of clinical cure in pneumonia in mITT populatio
located at the intersection of the column-defining treatment and the row-de
modified intention-to-treat population. VAN, vancomycin. LIN, linezolid. CEF2,
telavancin. TEI, teicoplanin. VAN/RIF, vancomycin plus rifampicin. Q/D, quinupCost analysis
Base-case analysis
Ten antibiotics (vancomycin, linezolid, tedizolid, telavan-
cin, dalbavancin, oritavancin, ceftaroline, tigecycline,
daptomycin, SXT/rifampin) were included in the MRSA
cSSSI model. Exclusions were fusidic acid and teicopla-
nin as the NMA showed they were less effective; JNJ-Q2
was not marketed; although omadacycline was approved
by FDA, it was not marketed currently; and ceftobiprole
has been discontinued. The costs and clinical outcomes
of the 10 treatments are summarized in Additional file 1:n. Comparisons should be read from left to right. The safety estimate is
fining treatment. Significant results are in bold and underlined. mITT,
ceftobiprole. SXT/RIT, trimethoprim/sulfamethoxazole plus rifampicin. TEL,
ristin/dalfopristin OR, odds ratio. CI, confidence interval
Table 2 Cost-effectiveness of antibiotics for treatment of cSSSI patients
Treatment strategy Total cost (USD) Incremental cost (USD) Total LY LY saveda ICER per LY saved
Vancomycin 15,254 7.52
SXT/rifampicin 13,419 -1836 7.68 0.16 Dominant
Linezolid 16,387 1133 7.92 0.40 2833
Tedizolid 17,353 2099 7.90 0.38 5523
Daptomycin 17,238 1984 7.84 0.32 6200
Ceftaroline 17,971 2717 7.82 0.30 9057
cSSSI complicated skin and soft structure infection, USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio, SXT trimethoprim/sulfamethoxazole
aCalculated as the average cost per patient and the average number of LY per patient in this strategy minus those of the treatment of vancomycin
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late the incremental cost-effectiveness ratio (ICER) for
other strategies, in accordance with current clinical
guidelines [4]. Tigecycline, oritavancin, dalbavancin,
telavancin, ceftaroline were less effective than vanco-
mycin, and the ICERs per LY saved corresponded to
>US$50,000. Therefore, these five options were not con-
sidered cost-effective treatment strategies. In the present
analysis, SXT/rifampicin was the dominant strategy,
however, there was insufficient data to recommend it
since the RCT studying SXT/rifampicin was of high risk.
The ICERs per LY saved for linezolid, tedizolid, dapto-
mycin and ceftaroline relative to vancomycin corre-
sponded to US$2833, US$5523, US$6200 and US$9057,
respectively (Table 2). These five antimicrobial agents
might be recommended for the treatment of MRSA
cSSSI within a range of WTP thresholds.
For MRSA pneumonia, teicoplanin, vancomycin, li-
nezolid, telavancin, SXT/rifampicin and quinupristin/
dalfopristin (Q/D) were evaluated in the cost analysis.
The total costs and effectiveness of the five treatment
options are shown in Additional file 1: Table S2. The
ICERs were calculated relative to vancomycin, which
was considered the baseline for other strategies. All
antibiotics including telavancin, Q/D and SXT/rifam-
picin were subordinate to vancomycin except linezolid
and teicoplanin, since the ICERs per LY saved corre-
sponded to >US$50,000. In the present analysis, teico-
planin was the dominant strategy, however, we were
unable to recommend this treatment due to the lim-
ited data with high risk study. The ICER per LY saved
for using linezolid over vancomycin was US$2185
(Table 3). These two antibiotics might be recom-
mended for treatment of MRSA pneumonia.Table 3 Cost-effectiveness of antibiotics for treatment of pneumoni
Treatment strategy Total cost (USD) Incremental cost (U
Vancomycin 16,346
Teicoplanin 12,487 − 3858
Linezolid 19,230 2884
USD US dollar, LY life-years, ICER incremental cost-effectiveness ratio
aCalculated as the average cost per patient and the average number of LY per patieSensitivity analysis
Deterministic sensitivity analyses revealed that the results
were most sensitive to the costs of antibiotics included in
the economic analysis and the duration of treating MRSA
cSSSI and HAP/VAP. For MRSA cSSSI, the unit cost of
daptomycin more than US$305 would result in more
cost-effective compared with linezolid. In HAP/VAP, the
unit cost of telavancin less than US$320 would make it
more cost-effective than linezolid. Other variations in a
single model parameter had no substantial impact on the
primary analyses both in cSSSI and pneumonia.
In cSSSI, probabilistic sensitivity analyses (PSA) dis-
played that SXT/rifampin, linezolid, tedizolid, daptomycin,
ceftaroline, tigecycline, dalbavancin, oritavancin and tela-
vancin had probabilities of 88.7, 87.7, 87.2, 86.7, 84.1, 72.4,
69.0, 52.1, and 50.0%, respectively, of being cost-effective
relative to vancomycin under the WTP threshold
($50,000). As for pneumonia, teicoplanin, linezolid, Q/D,
telavancin and SXT/rifampin had probabilities of 83.2,
60.0, 34.3, 26.3, 17.5%, respectively within the threshold.
Discussion
Our systematic review and NMA comprehensively eval-
uated the efficacy, safety, and cost-effectiveness of antibi-
otics used to treat MRSA cSSSI and pneumonia. We
found that for clinical cure linezolid and tedizolid were
superior to the other antibiotics in patients with cSSSI.
In terms of safety, there was no significant difference be-
tween any two interventions for total adverse events.
Our cost analysis showed that oxazolidinone and vanco-
mycin were cost-effective in the treatment of MRSA in-
fections and within a range of WTP thresholds. For
MRSA pneumonia, the efficacy of linezolid and vanco-
mycin were better than other antibiotics. As for safety,a patients
SD) Total LY LY saveda ICER per LY saved
9.84
10.80 0.96 Dominant
11.16 1.32 2185
nt in this strategy minus those of the treatment of vancomycin
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treatments for total adverse events. In the cost-analysis,
linezolid and vancomycin were cost-effective within a
range of WTP thresholds.
cSSSIs are common infections in everyday clinical
practice, resulting in high morbidity and health care cost
[34]. We found that linezolid had better efficacy in pa-
tients with cSSSI, which is consistent with guideline rec-
ommendations. Our findings are consistent with a
previous study [35] which highlighted that SXT/rifampi-
cin and linezolid had similar efficacy but lower cost [36].
Nevertheless only one RCT included in our NMA dir-
ectly compared SXT/rifampicin and linezolid, there is in-
sufficient evidence to make any conclusion. A recent
large meta-analysis [37] showed that linezolid was asso-
ciated with a significantly higher clinical cure rate and
reduced length of hospital stay compared with vanco-
mycin for cSSSI. The improved skin penetration of linez-
olid and its high bioavailability may explain the
improved clinical outcomes among patients receiving li-
nezolid [38]. Similarly, linezolid may be a cost-effective
alternative to vancomycin in the treatment of patients
with cSSSI [39, 40], which was consistent with our
analysis. Tedizolid, a novel oxazolidinone, showed com-
parable efficacy to linezolid in a phase 3 RCTs [41],
which was consistent with our results. Omadacycline
which belongs to a new class of compounds,
aminomethyl-cyclines, is considered a promising drug
for the treatment of severe MRSA infections [42]. RCTs
found that omadacycline was more effective than
linezolid; however, due to the limited number of studies
in our NMA, we are unable to conclude whether oma-
dacycline can be used as an alternative to linezolid.
Although there was no significant difference between
any of the treatments for total adverse events, attention
should still be paid to some adverse events for antibi-
otics (e.g., thrombocytopenia for linezolid, nephrotox-
icity for vancomycin).
Pneumonia is the second most common
hospital-acquired infections in adults, contributing to
inpatient mortality [43]. Previous studies compared the
efficacy of linezolid and vancomycin in the treatment of
MRSA pneumonia [44–47] with contradictory results.
Using NMA we showed that the clinical response with li-
nezolid is similar to vancomycin, which is consistent with
guideline recommendations. Furthermore, our analysis
showed that the efficacy of teicoplanin was better than the
other interventions, but differences were not statistically
significant. However, as only one RCT on teicoplanin was
included, this remains to be further verified. Although
there was no statistically significant difference among in-
cluded antibiotics, we should pay attention to several ad-
verse events for antimicrobial agents. Telavancin was
approved by FDA for the treatment of hospital-acquiredand ventilator-associated bacterial pneumonia caused by
Staphylococcus aureus [48]. To our knowledge, telavancin
has not been compared with linezolid in any clinical or
observational studies. Our study compared these two
drugs indirectly and found no significant differences in ef-
ficacy. Serious adverse events of telavancin can cause poor
clinical outcomes among patients, which may limit its ap-
plication in clinical practice. HAP caused an increase of
$11,897 to $25,072 per incident and was the leading cause
of death in all nosocomial infections [49]. In four pharma-
coeconomic analyses comparing vancomycin and linezolid
in the treatment of pneumonia, efficacy and cost data
were obtained from published RCTs [50–53]. Our results
confirmed the results of previous analyses and showed
that despite its higher cost, linezolid was cost-effective for
treatment of MRSA pneumonia.
Given the difficulties of assessing multiple RCTs to
directly compare individual antibiotics used to treat se-
vere MRSA infections, the use of NMA to compare the
relative efficacy and safety of new and traditional drugs
through indirect methods is recommended. Previous
studies have evaluated the effectiveness and safety of an-
tibiotics used for treating hospitalized adults with cSSSI
or pneumonia [14, 15, 54]. However, timely evaluation of
the latest treatment strategies in the era of antimicrobial
resistance is crucial for treatment decision making.
Our study has several limitations. First, most of the re-
search were published prior to the 2010 FDA guideline for
designing RCTs to evaluate antibiotics for cSSSI [20]. As a
consequence, the definition of cSSSI varied between stud-
ies. Second, the low quality of some research due to un-
clear bias risk and the possibility of publication bias, may
jeopardize the validity of our conclusions. Findings from
our analysis, however, were not affected by the results
from the research with high-risk of bias via sensitivity ana-
lysis. Third, the confidence intervals for some antibiotics
are really wide because of limited sample size. Therefore,
we recommend that larger research should be included in
order to make a more accurate conclusion. Fourth, due to
various adverse events of involved antibiotics, we only de-
scribe the probability and costs associated with primary
adverse events (e.g thrombocytopenia for linezolid or
nephrotoxicity for vancomycin). Ignoring differences in
the probability and costs of adverse events may influence
results. Finally, our cost analysis only evaluated linezolid
intravenous formulations. Linezolid has the main advan-
tage of oral administration, with almost 100% bioavailabil-
ity [55]. Given the high bioavailability of linezolid [56],
future studies should consider the cost-effectiveness of
oral dosage forms to comprehensively evaluate the clinical
value of antibiotics for the treatment of MRSA infections.
This study might provide new insights of therapeutic
choices for patients with MRSA infections whilst awaiting
the arrival of higher quality evidence.
Zhang et al. Antimicrobial Resistance and Infection Control            (2019) 8:72 Page 10 of 11Conclusions
Considering efficacy, safety, and cost-effectivenes, linezo-
lid and tedizolid showed their superiority in MRSA
cSSSI; while linezolid might be recommended to treat
MRSA pneumonia. Although vancomycin was not
cost-effective in pharmacoeconomic evaluation, it is still
the first-line treatment for MRSA infection in the clin-
ical practice. The approach used in this study might as-
sist in revisiting therapeutic choices for patients with
MRSA infections while awaiting the arrival of higher
quality evidence.
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